Guobang Pharma Ltd. Class A

Guobang Pharma Ltd. Class A

SSSE:605507
15.83
CNY
+0.33
(+2.13%)
0.80EPS
22.48P/E
14.15BMarket Cap
Apr 12Next Earn

Total Valuation

CNY

As of September 30, 2026, Guobang Pharma Ltd. Class A carries a market capitalization of 14.15B, placing it among publicly traded companies globally. Its enterprise value stands at 12.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.15B
Enterprise Value12.61B

Important Dates

Guobang Pharma Ltd. Class A's next confirmed earnings release is scheduled for April 12, 2027.

Earnings Date4/12/2027

Share Statistics

As of September 30, 2026, Guobang Pharma Ltd. Class A has 782.35M shares outstanding.

Shares Outstanding782.35M

Valuation Ratios

As of September 30, 2026, Guobang Pharma Ltd. Class A trades at a trailing price-to-earnings ratio of 22.48. The price-to-sales ratio is 2.28, and the price-to-book ratio stands at 1.66.

PE Ratio22.48
PS Ratio2.28
PB Ratio1.66
P/TBV Ratio1.74

Enterprise Valuation

As of September 30, 2026, Guobang Pharma Ltd. Class A trades at an EV/EBITDA multiple of 17.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.61B versus a market cap of 14.15B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.06
EV / EBITDA17.44
EV / EBIT17.44

Financial Position

As of September 30, 2026, Guobang Pharma Ltd. Class A maintains a current ratio of 2.45, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.19, indicating elevated leverage, while an interest coverage ratio of 33.00 demonstrates strong ability to service its debt obligations.

Current Ratio2.45
Quick Ratio0.98
Debt / Equity11.19
Debt / EBITDA1.32
Interest Coverage33.00

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.44M in revenue per employee across its workforce of 4,251.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.44M
Employee Count4,251.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A recorded 89.26M in income tax expense. That works out to an effective tax rate of 12.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 710.58M, leaving 621.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax89.26M
Effective Tax Rate12.56

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guobang Pharma Ltd. Class A's stock has declined approximately 4.43% over the past 52 weeks. The 50-day moving average sits at 16.18, while the 200-day moving average is 16.90.

52-Week Price Change-4.43%
50-Day Moving Average16.18
200-Day Moving Average16.90

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A generated 6.13B in revenue and converted that into 621.94M in net income, yielding earnings per share of 0.80. EBITDA reached 722.94M, while operating income came in at 797.83M.

Revenue6.13B
Gross Profit1.43B
Operating Income797.83M
Pretax Income710.58M
Net Income621.94M
EBITDA722.94M
EBIT722.94M
Earnings Per Share (EPS)0.80

Balance Sheet

CNY

As of September 30, 2026, Guobang Pharma Ltd. Class A holds 2.50B in cash and equivalents against 952.93M in total debt, resulting in a net debt position of -692.44M. Total book value stands at 8.51B, with working capital of 3.68B providing operational flexibility.

Cash & Cash Equivalents2.50B
Total Debt952.93M
Net Debt-692.44M
Equity (Book Value)8.51B
Book Value Per Share10.88
Working Capital3.68B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-360.30M

Margins

Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A posted a gross margin of 23.26, reflecting its pricing power and cost economics. The operating margin of 13.01 and net profit margin of 10.15 provide insight into operational efficiency.

Gross Margin23.26
Operating Margin13.01
Pretax Margin11.59
Profit Margin10.15
EBITDA Margin11.79

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A paid dividends of 0.46 per share. The dividend payout ratio of 57.03 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guobang Pharma Ltd. Class A shareholders.

Dividend Per Share0.46
Payout Ratio57.03
Shareholder Yield2.51

Stock Splits

Guobang Pharma Ltd. Class A's most recent stock split took place on May 29, 2026 with a 5:7 split ratio.

Last Split Date5/29/2026
Split Ratio5:7

Scores

As of September 30, 2026, Guobang Pharma Ltd. Class A has an Altman Z-Score of 4.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.85